Executive Chairman buys 50,000 shares

Summary by AI ^BETAClose X

Fortis Frontier PLC announced that its Executive Chairman, Adam Reynolds, purchased 50,000 ordinary shares at 8.5 pence per share on January 5, 2026, increasing his total interest to 750,886 shares, representing approximately 1.44% of the issued share capital. Additionally, Mr. Reynolds surrendered options for 66,667 ordinary shares with a 52.5p exercise price for nil consideration. This transaction, along with the surrender of options, could be viewed positively by the market as a sign of insider confidence in the company's future prospects as it operates as an AIM Rule 15 cash shell.

Disclaimer*

Fortis Frontier PLC

05 January 2026

Fortis Frontier PLC

("Fortis Frontier" or the "Company")

Executive Chairman buys 50,000 shares

Fortis Frontier PLC (AIM: FORF), an AIM Rule 15 cash shell (formerly MyHealthChecked PLC), announces that it was notified that on 5 January 2026 that Adam Reynolds, Executive Chairman, purchased a total of 50,000 (fifty thousand) ordinary shares of 1.5 pence each in the Company ("Ordinary Shares") at a price of 8.5 pence per Ordinary Share. Following this transaction, Adam Reynolds' total direct and indirect interest in the Company is 750,886 Ordinary Shares representing approximately 1.44% of the Company's total issued share capital.

The Notification of Dealing Form required in accordance with UK MAR is set out below.

In addition, Adam Reynolds has also surrendered options over 66,667 ordinary shares granted on 28 July 2021, with an exercise price of 52.5p for nil consideration.

For further information contact:

Fortis Frontier PLC			www.fortisfrontierplc-ir.com
Adam Reynolds, Executive Chairman			via Walbrook PR

SPARK Advisory Partners Limited (NOMAD)			Tel: +44 (0)20 3368 3550
Neil Baldwin

Dowgate Capital Limited (Broker)		Tel: +44 (0)20 3903 7715
David Poutney / Russell Cook

Walbrook PR Ltd (Media & IR)	Tel: +44 (0)20 7933 8780 or fortisfrontier@walbrookpr.com
Paul McManus / Alice Woodings		Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

About Fortis Frontier PLC

On 10 November 2025 MyHealthChecked PLC completed the disposal of its trading subsidiary, Concepta Diagnostics Limited, becoming an AIM Rule 15 Cash Shell, as defined in the AIM Rules for Companies. On the same day the Company changed its name to Fortis Frontier PLC. The Board is now carefully considering the strategic options available to it in order to maximise shareholder value.


1	Details of the person discharging managerial responsibilities / person closely associated

a)	Name	Adam Reynolds

2	Reason for the notification

a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial Notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)	Name	FORTIS FRONTIER PLC
b)	LEI	213800RBHY6LZDG13168

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)	Description of the financial instrument, type of instrument	Ordinary Shares

	Identification code	ISIN: GB00BYZ2R301

b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			8.5 pence	50,000

d)	Aggregated information

	- Aggregated volume	N/A - Single Transaction

	- Price

e)	Date of the transaction	5 January 2026

f)	Place of the transaction	London Stock Exchange - AIMX

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END